Calendario›REGN›ALN-PNP

ALN-PNP

A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor

Ensayo de REGENERON PHARMACEUTICALS, INC. en Nonalcoholic Fatty Liver Disease (NAFLD) · Nonalcoholic Steatohepatitis (NASH) · Genetic Risk Factor (del registro, en inglés).

Más ensayos de: Esteatohepatitis no alcohólica.

Fase

Fase 1

Estado

Completado

Participantes

9

previstos

Centros

5

Fin del objetivo primario

jul 2025

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en may 2024.

Qué mide

Incidence of treatment-emergent adverse events (TEAEs) (del registro, en inglés) (hasta 253 dias)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching an experimental drug called ALN-PNP. This study is focused on participants who are known to have nonalcoholic fatty liver disease (NAFLD), and a specific variant of the patatin-like phospholipase domain containing 3 (PNPLA3) gene. The aim of this study is to see how safe, tolerable, and effective the study drug is. This study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How the study drug works to change liver fat content in NAFLD * How much study drug and study drug metabolites (byproduct of the body breaking down the study drug) are in your blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) * Better understanding of the study drug and NAFLD

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06024408), actualizada en jul 2025.